The Vanguard Group 13D and 13G filings for Halozyme Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:06 pm Sale |
2023-12-29 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,259,514 10.040% |
-269,116 (-1.99%) |
Filing |
| 2023-06-09 2:15 pm Purchase |
2023-05-31 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,528,630 10.270% |
224,783 (+1.69%) |
Filing |
| 2023-02-09 11:22 am Sale |
2022-12-30 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,303,847 9.840% |
-238,742 (-1.76%) |
Filing |
| 2022-12-12 3:09 pm Purchase |
2022-11-30 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,542,589 10.020% |
46,676 (+0.35%) |
Filing |
| 2022-02-10 08:17 am Purchase |
2021-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,495,913 9.590% |
346,210 (+2.63%) |
Filing |
| 2021-02-10 10:57 am Sale |
2020-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
The Vanguard Group | 13,149,703 9.730% |
-873,756 (-6.23%) |
Filing |